The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade.
This report on the U.S. market for OTC private label products presents an in-depth analysis of the performance of various OTC private label drugs and healthcare products, including:
- Cough, Cold, Allergy & Sinus
- First Aid
- Foot Care
- Contraceptives/Family Planning
- Sleeping Aids
- Eye care
- Miscellaneous Remedies
The report provides sales figures for private label products in relation to branded products in each category, analyzes average unit pricing, details consumer demographics and attitudes toward private label products, reports ad spend and new product introductions by the various retailers, and discusses the trends and issues shaping the private label market of the future. In addition, profiles of the major manufacturers and retailers outline the financial positions and new developments among the major private label players.
The reports research methodology includes a combination of primary and secondary research. Information Resources Inc. (IRI) and Simmons Market Research Bureau (SMRB) provided primary research findings; secondary research included such material as published reports, news stories, and company literature and documents. The information on new product introductions and their salient features are provided by the ProductScan report for the period January 2004 to October 2005. The estimates on consumer advertising expenditures are based on data compiled by TNS Media Intelligence, the leading provider of strategic advertising and marketing communications intelligence.
Secondary research information has been obtained from trade association publications, business journals, government agencies, and other publicly available information. The study involved comprehensive research of secondary sources such as company literature, databases, investment reports and reports in medical and business journals.